Unilens Vision Inc. To Be Acquired By Valeant Pharmaceuticals

0
1282

Unilens Vision Inc. (OTCQX: UVIC) announced today that they have entered into a definitive agreement under which a subsidiary of Valeant Pharmaceuticals International, will acquire all of the outstanding common stock of Unilens Vision Inc. (Unilens) for $12.75 per share in cash, or a total enterprise value of approximately $28 million, which includes approximately $5 million in debt. The transaction was unanimously approved by Unilens’ Board of Directors and is expected to close by September 1, 2015, subject to stockholder approval and customary closing conditions. Unilens anticipates holding a special meeting of its stockholders to consider and adopt the Agreement and Plan of Merger in the second half of August 2015.
The acquisition will bolster Valeant’s specialty contact lens business, and provide a complete line of specialty lens products to the Eye Care Professional. The Unilens C- Vue brands of customized and disposable contact lenses will continue to be marketed and sold directly to practitioners.
Michael J. Pecora, Chairman of the Board, Chief Executive Officer and President of Unilens, stated, “We are very pleased to sign a definitive agreement with Valeant, which creates immediate value for our stockholders. The combination of Unilens’ world class technology and its leading customized lens business with Valeant will create a strong portfolio of products enhancing our commitment to providing the best possible visual outcomes throughout the optical industry. In the coming months we will be working closely with the Valeant team to ensure a smooth transition.”

NO COMMENTS